Dr. von Minckwitz on Breast Cancer Responses

Gunter von Minckwitz, MD, PhD
Published: Tuesday, May 07, 2013

Gunter von Minckwitz, MD, PhD, Chairman, German Breast Group, Professor of Gynecology, University of Frankfurt, Germany, discusses the current unsolved medical situation regarding patients with breast cancer who do not respond to treatment.

In most breast cancer subtypes, standard treatment strategy is understood: patients with hormone receptor-positive disease receive endocrine treatment and HER2-positive patients receive the remainder of their treatment. Patients with triple-negative disease have nothing, von Minckwitz says.

According to data, adding chemotherapy in triple-negative patients before surgery demonstrates no benefit, forcing a need for new options. There are two new studies upcoming: looking at T-DM1 in HER2-positive disease for non-responding patients and looking for a CDK inhibitor in hormone receptor-positive, HER2-negative disease without pathologic complete response and a high risk for relapse.

Gunter von Minckwitz, MD, PhD, Chairman, German Breast Group, Professor of Gynecology, University of Frankfurt, Germany, discusses the current unsolved medical situation regarding patients with breast cancer who do not respond to treatment.

In most breast cancer subtypes, standard treatment strategy is understood: patients with hormone receptor-positive disease receive endocrine treatment and HER2-positive patients receive the remainder of their treatment. Patients with triple-negative disease have nothing, von Minckwitz says.

According to data, adding chemotherapy in triple-negative patients before surgery demonstrates no benefit, forcing a need for new options. There are two new studies upcoming: looking at T-DM1 in HER2-positive disease for non-responding patients and looking for a CDK inhibitor in hormone receptor-positive, HER2-negative disease without pathologic complete response and a high risk for relapse.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x